We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health (CVS) Up 8.6% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
It has been about a month since the last earnings report for CVS Health (CVS - Free Report) . Shares have added about 8.6% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is CVS Health due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
CVS Health Q2 Earnings Top Estimates on Balanced Growth in All Arms
CVS Health second-quarter 2021 adjusted earnings per share (EPS) of $2.42 declined 8.3% year over year but exceeded the Zacks Consensus Estimate by 16.9%. The adjusted EPS figure takes into account certain asset amortization costs and acquisition-related integration costs along with other adjustments.
On a reported basis, the company’s earnings of $2.10 per share fell 7.1% year over year.
Total revenues in the second quarter rose 11.1% year over year to $72.62 billion. The top line also beat the Zacks Consensus Estimate by 3.6%.
Quarter in Detail
Pharmacy Services revenues were up 9.8% to $38.31 billion in the reported quarter. Increased pharmacy claims volume, growth in specialty pharmacy and brand inflation were partially offset by continued price compression in the quarter.
Total pharmacy claims processed rose 11.2% on a 30-day equivalent basis, attributable to strong net new business, COVID-19 vaccinations and increased new therapy prescriptions. Without considering the COVID-19 vaccinations, total pharmacy claims processed increased 8.4% on a 30-day equivalent basis.
Revenues from CVS Health’s Retail/LTC segment were up 14.2% year over year to $24.73 billion. In the quarter, benefit from increased prescription volume, COVID-19 vaccinations and diagnostic testing and higher front store revenues across all product categories were partially offset by continued pharmacy reimbursement pressure.
Within Health Care Benefits segment, the company registered revenues worth $20.53 billion in the second quarter, up 11.1% year over year. The improvement was primarily driven by growth in the Government Services business, partially offset by the unfavorable impact of the repeal of the HIF (Health Insurer Fee) for 2021.
Margin
Total cost (including Benefit Cost) rose 14.3% to $59.42 billion in the second quarter. Gross profit fell 1.1% to $13.19 billion and accordingly gross margin contracted 226 basis points (bps) to 18.2%. Operating margin in the quarter under review fell 121 bps to 5.9% on a 7.6% decline in operating profit to $4.33 billion.
2021 Guidance
CVS Health raised its 2021 adjusted EPS guidance. Adjusted EPS is expected in the band of $7.70-$7.80 (compared with the earlier provided range of $7.56-$7.68). The Zacks Consensus Estimate for 2021 earnings is pegged at $7.66.
Full-year operating cash flow projection has been raised to the range of $12.5 billion-$13 billion ($12 billion-$12.50 billion).
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision.
VGM Scores
At this time, CVS Health has a great Growth Score of A, though it is lagging a bit on the Momentum Score front with a B. Charting a somewhat similar path, the stock was allocated a grade of A on the value side, putting it in the top 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, CVS Health has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CVS Health (CVS) Up 8.6% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for CVS Health (CVS - Free Report) . Shares have added about 8.6% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is CVS Health due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
CVS Health Q2 Earnings Top Estimates on Balanced Growth in All Arms
CVS Health second-quarter 2021 adjusted earnings per share (EPS) of $2.42 declined 8.3% year over year but exceeded the Zacks Consensus Estimate by 16.9%. The adjusted EPS figure takes into account certain asset amortization costs and acquisition-related integration costs along with other adjustments.
On a reported basis, the company’s earnings of $2.10 per share fell 7.1% year over year.
Total revenues in the second quarter rose 11.1% year over year to $72.62 billion. The top line also beat the Zacks Consensus Estimate by 3.6%.
Quarter in Detail
Pharmacy Services revenues were up 9.8% to $38.31 billion in the reported quarter. Increased pharmacy claims volume, growth in specialty pharmacy and brand inflation were partially offset by continued price compression in the quarter.
Total pharmacy claims processed rose 11.2% on a 30-day equivalent basis, attributable to strong net new business, COVID-19 vaccinations and increased new therapy prescriptions. Without considering the COVID-19 vaccinations, total pharmacy claims processed increased 8.4% on a 30-day equivalent basis.
Revenues from CVS Health’s Retail/LTC segment were up 14.2% year over year to $24.73 billion. In the quarter, benefit from increased prescription volume, COVID-19 vaccinations and diagnostic testing and higher front store revenues across all product categories were partially offset by continued pharmacy reimbursement pressure.
Within Health Care Benefits segment, the company registered revenues worth $20.53 billion in the second quarter, up 11.1% year over year. The improvement was primarily driven by growth in the Government Services business, partially offset by the unfavorable impact of the repeal of the HIF (Health Insurer Fee) for 2021.
Margin
Total cost (including Benefit Cost) rose 14.3% to $59.42 billion in the second quarter. Gross profit fell 1.1% to $13.19 billion and accordingly gross margin contracted 226 basis points (bps) to 18.2%. Operating margin in the quarter under review fell 121 bps to 5.9% on a 7.6% decline in operating profit to $4.33 billion.
2021 Guidance
CVS Health raised its 2021 adjusted EPS guidance. Adjusted EPS is expected in the band of $7.70-$7.80 (compared with the earlier provided range of $7.56-$7.68). The Zacks Consensus Estimate for 2021 earnings is pegged at $7.66.
Full-year operating cash flow projection has been raised to the range of $12.5 billion-$13 billion ($12 billion-$12.50 billion).
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision.
VGM Scores
At this time, CVS Health has a great Growth Score of A, though it is lagging a bit on the Momentum Score front with a B. Charting a somewhat similar path, the stock was allocated a grade of A on the value side, putting it in the top 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, CVS Health has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.